Brussels - Delayed Quote EUR

Ion Beam Applications SA (IBAB.BR)

10.58

+0.04

+(0.38%)

As of 3:47:20 PM GMT+2. Market Open.

IBA – ACQUISITION OF OWN SHARES

Immediate Release – April 18th, 2025 Louvain-la-Neuve, Belgium, April 18th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate wit

GlobeNewswire 9 days ago

IOBCF
IBA long-term strategy presented at 2025 Capital Markets Day

Announcement of the appointment of Catherine Vandenborre as CFO Louvain-la-Neuve, Belgium, 07 April, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, hosted its Capital Markets Day (CMD) today at its headquarters in Louvain-la-Neuve, Belgium, and via live webcast. During the event, Olivier Legrain (CEO), Henri de Romrée (Deputy CEO), and the IBA management team outlined the company's purpose, vision, and strategy to shareholders, investors,

GlobeNewswire 20 days ago

IOBCF
IBA to share long-term growth strategy at upcoming 2025 Capital Markets Day

Louvain-la-Neuve, Belgium, 04 April, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, will be hosting a Capital Markets Day (CMD) this coming Monday 7 April from 2pm to 5:00pm CEST (8am ET to 11:00am ET) at its headquarters in Louvain-la-Neuve, Belgium, and via live webcast. At the event IBA’s management team will outline the company’s strategic roadmap and long-term growth ambitions. The agenda is outlined below: Webcast open: 2pmPurpose, V

GlobeNewswire 24 days ago

IOBCF
Tri-Service General Hospital in Taiwan to install proton therapy system from IBA

The ProteusONE system is claimed to offer compact design and upgradability.

Hospital Management 25 days ago

IBAB.BR
+0.38%
IBA signs contract for a Proteus®ONE solution to be installed at the Tri-Service General Hospital in Taiwan

Louvain-La-Neuve, Belgium, April 2nd, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract for the supply of a Proteus®ONE1 compact proton therapy solution to be located at the Tri-Service General Hospital in Taipei, Taiwan. The contract includes the supply of a Proteus®ONE system and a Quality Assurance package from

GlobeNewswire 26 days ago

IOBCF
IBA – Share buyback

Louvain-la-Neuve, Belgium, March 24th, 2025 - Ion Beam Applications SA (IBA) announces today the launch of a share buyback program, effective as of March 25th, 2025, in application of article 7:215 of the Belgian Companies and Associations Code. By a decision of the Board of Directors of March 18th, 2025, taken pursuant to the authorization given by the EGM of September 4th, 2023, IBA launched a program to buy back own shares through a mandate given to a market intermediary. This program covers

GlobeNewswire last month

IOBCF
Ion Beam Applications SA (IOBCF) (FY 2024) Earnings Call Highlights: Record Revenue and ...

Ion Beam Applications SA (IOBCF) reports a 7% revenue increase and outlines future profitability strategies amid strong order intake and strategic R&D investments.

GuruFocus.com last month

IBAB.BR
+0.38%
IBA reports solid Full Year 2024 results

Read the entire full year 2024 results press release here Louvain-la-Neuve, Belgium, 20 March 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the 2024 financial year. Record-high revenue and return to profitability in 2024 driven by well-executed backlog conversion Net sales rose 7% to €498.2 million1, with Other Accelerators increasing by 18%Gross margin improvement to 33.3% vs. 28.8% in 2023, driven by hi

GlobeNewswire last month

IOBCF
Apollo Hospitals to procure proton therapy solution from IBA

Apollo Hospitals anticipates beginning patient treatments using the systems by 2028.

Hospital Management last month

APOLLOHOSP.NS

IBAB.BR
+0.38%
IBA and Apollo Hospitals sign a term sheet for one Proteus®ONE system plus a second one in option to be installed in India

Louvain-La-Neuve, Belgium, March 04, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a term sheet with Apollo Hospitals Enterprise Limited (AHEL) for the supply of one Proteus®ONE1 compact proton therapy solution plus a second one in option. Apollo will therefore expand access to proton therapy in India. The term sheet was signed in th

GlobeNewswire last month

IOBCF
IBA Notice of Full Year 2024 Results and Conference Call

FY24 results meeting to take place as a hybrid event on Thursday, 20 March 2025 at 2:30pm CET Louvain-la-Neuve, Belgium, 27 February 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the full year 2024 on Thursday, 20 March 2025 at 7am CET. Conference Call Information IBA’s management team will host a hybrid event, including a conference call and webcast conducted in English, t

GlobeNewswire last month

IOBCF
IBA and Jabil sign contract to install a Be-Wide X-ray solution in Mississippi, USA

Louvain-la-Neuve, Belgium, February 25, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial irradiation, and Jabil Inc. a global leader in engineering, manufacturing, and supply chain solutions, announced today they have signed a contract for the installation of a Be-Wide X-ray solution in a greenfield site in Byhalia, Mississippi, USA, to expand Jabil’s sterilization capabilities. The Be Wide

GlobeNewswire last month

IOBCF
Notice of Capital Markets Day - Save the Date

Louvain-la-Neuve, Belgium, 18 February, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, will host a Capital Markets Day (CMD) for investors and analysts on Monday 7 April 2025 at 2pm CET / 1pm GMT / 8am ET. The event will include presentations, panel discussions and Q&A sessions led by IBA’s management team with speakers from across the Group. Attendees will have the opportunity to gain valuable insights into IBA’s strategy, including selec

GlobeNewswire 2 months ago

IOBCF
IBA - Regulated Information

IBA SA – Section 15 of the transparency act February 11th 6:00, 2025 Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions (Belgian Gazette 12.VI.2007) (hereinafter, the “Law”) Under this provision: "[...] the issuer publishes the total capital, the total number of securities conferring the right to vote and voting rights, as well as, by categ

GlobeNewswire 2 months ago

IOBCF
IBA – Transparency Notification IBA SA

IBA – TRANSPARENCY NOTIFICATION (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, February 11th, 2025 06:00 Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the n

GlobeNewswire 2 months ago

IOBCF
IBA – Transparency Notification

IBA – TRANSPARENCY NOTIFICATION (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, February 11th, 2025 06:00 Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the n

GlobeNewswire 2 months ago

IOBCF
Framatome and IBA to partner to develop an Astatine-211 Cyclotron Network in Europe and the USA

Louvain-La-Neuve, Belgium, and Paris, France, 7 February 2025 - Framatome, an international leader in nuclear energy committed to developing products and services for the healthcare industry, and IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today announced they have signed a Memorandum Of Understanding to start a strategic partnership aimed at advancing industrial-scale produc

GlobeNewswire 2 months ago

IOBCF
IBA signs Proteus®ONE system contract with AIG in Hyderabad, India

Louvain-La-Neuve, Belgium, February 06, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a binding agreement with the Asian Institute of Gastroenterology (AIG) for the supply of a Proteus®ONE1 compact proton therapy system to be located at the new Oncology Centre within AIG Hospitals’ Gachibowli campus in Hyderabad, India. T

GlobeNewswire 2 months ago

IOBCF
IBA and Wallonie Entreprendre International secure 30% stake in mi2-factory to support improved efficiency of silicon carbide-powered devices

Louvain-La-Neuve, Belgium, 21 January 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and Wallonie Entreprendre International (WE International), the international branch of the Walloon public investment company, today announce a joint strategic investment of EUR 5 million each in mi2-factory, a start-up and spin-off from the University of Applied Sciences Jena, Germany. This investment secures a 15% stake for IBA and a 15% stake for WE Int

GlobeNewswire 3 months ago

IOBCF
IBA announces Chief Financial Officer transition

Louvain-La-Neuve, Belgium, January 17, 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that Soumya Chandramouli will be stepping down from her role as Chief Financial Officer (“CFO”), effective 31 January 2025. Henri de Romrée, Deputy CEO, will oversee the financial direction at Group level until a new CFO has been appointed. Thomas Peve

GlobeNewswire 3 months ago

IOBCF

Performance Overview

Return	IBAB.BR	BEL 20 (^BFX)
YTD	-20.81%	+2.61%
1-Year	-16.70%	+11.91%
3-Year	-28.99%	+5.95%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ion Beam Applications SA (IBAB.BR)

IBA – ACQUISITION OF OWN SHARES

IBA long-term strategy presented at 2025 Capital Markets Day

IBA to share long-term growth strategy at upcoming 2025 Capital Markets Day

Tri-Service General Hospital in Taiwan to install proton therapy system from IBA

IBA signs contract for a Proteus®ONE solution to be installed at the Tri-Service General Hospital in Taiwan

IBA – Share buyback

Ion Beam Applications SA (IOBCF) (FY 2024) Earnings Call Highlights: Record Revenue and ...

IBA reports solid Full Year 2024 results

Apollo Hospitals to procure proton therapy solution from IBA

IBA and Apollo Hospitals sign a term sheet for one Proteus®ONE system plus a second one in option to be installed in India

IBA Notice of Full Year 2024 Results and Conference Call

IBA and Jabil sign contract to install a Be-Wide X-ray solution in Mississippi, USA

Notice of Capital Markets Day - Save the Date

IBA - Regulated Information

IBA – Transparency Notification IBA SA

IBA – Transparency Notification

Framatome and IBA to partner to develop an Astatine-211 Cyclotron Network in Europe and the USA

IBA signs Proteus®ONE system contract with AIG in Hyderabad, India

IBA and Wallonie Entreprendre International secure 30% stake in mi2-factory to support improved efficiency of silicon carbide-powered devices

IBA announces Chief Financial Officer transition

Performance Overview